David Chen, PharmD, explains how physician-led formulary decisions — not rebates — power Kaiser Permanente’s biosimilar strategy, and why he thinks other health systems could do the same.
|Slideshows|April 15, 2019
5 Myths About Biosimilars-And the Facts
Author(s)Nicholas Hamm
The falsehoods being spread about biosimilars that don’t match up with reality.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
2
Heart data in sleep study predicts atrial fibrillation, heart failure years in advance
3
For bronchiectasis, a new era of guideline-guided care | CHEST 2026
4
Now is the time to get ready for 2027 changes in prior authorization, MA Star Ratings and others in federal healthcare law and regulations
5